Showing 1 - 5 of 5 Transplant Trials

Status: Enrolling

Investigator: Arvind Bhimaraj

Study Coordinator: Marcos DeOliveira

Phone: 171.344.19837

The objective of this registry is to observe short and long term clinical outcomes in heart transplant recipients who receive regular AlloMap testing as part of allograft rejection surveillance ... Read more >

Status: Open Not Enrolling

Investigator: Richard Knight

Study Coordinator: Adam Daniels

Phone: 713.441.6232

The purpose of this study is to evaluate the efficacy of ASP0113 compared to placebo in reducing the incidence of cytomegalovirus (CMV) viremia in CMV-seronegative subjects receiving a kidney from a CMV-seropositive donor. This study will also e ... Read more >

Status: Open Not Enrolling

Investigator: Richard Knight

Study Coordinator: Alejandro De La Torre

Phone: 713.441.6396

The primary purpose is to assess the benefits and risks of changing from Cyclosporine or Tacrolimus to Belatacept between 6-36 months after kidney transplant. ... Read more >

Status: Enrolling

Investigator: Barry Trachtenberg

Study Coordinator: Marcos DeOliveira

Phone: 171.344.19837

The purpose of this study is to evaluate the efficacy and safety of a single transendocardial delivery in the cardiac catheterization laboratory of human bone marrow-derived allogeneic MPCs (rexlemestrocel-L) for improvement in clinical outcomes ... Read more >

Status: Enrolling

Investigator: Ahmed Gaber

Study Coordinator: Darrel Cleere

Phone: 713.441.6232

Rabbit antithymocyte globulin (rATG) is approved for the treatment of acute rejection following kidney transplantation and is routinely administered as a series of 5-7 consecutive daily doses via central intravenous catheter. This prolonged cour ... Read more >

Live Chat Available